PFIZER INC
PFEAPI behind this page
PFE Q1 2026 request
Playground key active
/api/financials?ticker=PFE&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue (Q) | — | — | — |
Show Product Lines breakouts |
|||
| Product | 11,715 | 11,294 | +3.7% |
| Royalty | 396 | 308 | +28.6% |
| Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer | 2,339 | 2,113 | +10.7% |
Show Product Lines breakouts |
|||
| Total Alliance revenues [Member] | 2,339 | 2,113 | +10.7% |
| Revenue | 14,451 | 13,715 | +5.4% |
Show Product Lines breakouts |
|||
| Abrysvo [Member] · Biopharma [Member] | 180 | 131 | +37.4% |
| Adcetris [Member] · Biopharma [Member] | 190 | 218 | -12.8% |
| All Other Hospital and Biosimilars [Member] · Biopharma [Member] | 953 | 901 | +5.8% |
| All other Oncology [Member] · Biopharma [Member] | 376 | 377 | -0.3% |
| All other Primary Care [Member] · Biopharma [Member] | 654 | 609 | +7.4% |
| All other Specialty Care [Member] · Biopharma [Member] | 579 | 486 | +19.1% |
| Bosulif [Member] · Biopharma [Member] | 129 | 151 | -14.6% |
| Braftovi/Mektovi [Member] · Biopharma [Member] | 174 | 136 | +27.9% |
| Cibinqo [Member] · Biopharma [Member] | 76 | 58 | +31.0% |
| Comirnaty [Member] · Biopharma [Member] | 232 | 565 | -58.9% |
| Eliquis [Member] · Biopharma [Member] | 2,166 | 1,923 | +12.6% |
| Elrexfio [Member] · Biopharma [Member] | 80 | 60 | +33.3% |
| Enbrel (Outside the U.S. and Canada) [Member] · Biopharma [Member] | 138 | 140 | -1.4% |
| FSME-IMMUN/TicoVac [Member] · Biopharma [Member] | 81 | 63 | +28.6% |
| Genotropin [Member] · Biopharma [Member] | 93 | 95 | -2.1% |
| Ibrance [Member] · Biopharma [Member] | 1,008 | 977 | +3.2% |
| Inflectra [Member] · Biopharma [Member] | 182 | 153 | +19.0% |
| Inlyta [Member] · Biopharma [Member] | 214 | 219 | -2.3% |
| Lorbrena [Member] · Biopharma [Member] | 305 | 222 | +37.4% |
| Nurtec ODT/Vydura [Member] · Biopharma [Member] | 353 | 248 | +42.3% |
| Octagam [Member] · Biopharma [Member] | 122 | 88 | +38.6% |
| Oncology Biosimilars [Member] · Biopharma [Member] | 409 | 264 | +54.9% |
| Orgovyx [Member] · Biopharma [Member] | 109 | 76 | +43.4% |
| Padcev [Member] · Biopharma [Member] | 591 | 426 | +38.7% |
| Paxlovid [Member] · Biopharma [Member] | 186 | 491 | -62.1% |
| Pfizer CentreOne [Member] | 289 | 273 | +5.9% |
| Prevnar Family [Member] · Biopharma [Member] | 1,690 | 1,660 | +1.8% |
| Sulperazon (Outside the U.S. and Canada) [Member] · Biopharma [Member] | 199 | 164 | +21.3% |
| Talzenna [Member] · Biopharma [Member] | 50 | 40 | +25.0% |
| Tivdak [Member] · Biopharma [Member] | 33 | 33 | 0.0% |
| Tukysa [Member] · Biopharma [Member] | 122 | 102 | +19.6% |
| Vyndaqel family [Member] · Biopharma [Member] | 1,602 | 1,486 | +7.8% |
| Xeljanz [Member] · Biopharma [Member] | 180 | 128 | +40.6% |
| Xtandi [Member] · Biopharma [Member] | 444 | 458 | -3.1% |
| Zavicefta (Outside the U.S. and Canada) [Member] · Biopharma [Member] | 150 | 135 | +11.1% |
| Zithromax [Member] · Biopharma [Member] | 112 | 158 | -29.1% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | 14,161 | 13,441 | +5.4% |
| Biopharma [Member] · Global Hospital and Biosimilars Division [Member] | 1,242 | 1,020 | +21.8% |
| Biopharma [Member] · Hospital and Biosimilars [Member] | 1,854 | 1,639 | +13.1% |
| Biopharma [Member] · International Commercial Division [Member] | 5,233 | 4,849 | +7.9% |
| Biopharma [Member] · Oncology [Member] | 3,826 | 3,494 | +9.5% |
| Biopharma [Member] · Operating Segments | 14,161 | 13,441 | +5.4% |
| Biopharma [Member] · Primary Care [Member] | 5,542 | 5,692 | -2.6% |
| Biopharma [Member] · Specialty Care [Member] | 2,939 | 2,616 | +12.3% |
| Biopharma [Member] · U.S. Commercial Division [Member] | 7,686 | 7,572 | +1.5% |
Show Geography breakouts |
|||
| International Developed Markets [Member] | 3,426 | 3,178 | +7.8% |
| International Emerging Markets [Member] | 2,293 | 2,163 | +6.0% |
| US | 8,731 | 8,374 | +4.3% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 289 | 273 | +5.9% |
| Cost of Revenue | 3,548 | 2,845 | +24.7% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | 3,034 | 2,314 | +31.1% |
| Selling, General & Administrative | 2,961 | 3,031 | -2.3% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | 2,131 | 2,186 | -2.5% |
| Research And Development Expense Excluding Acquired In Process Cost | 2,490 | 2,203 | +13.0% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | 2,137 | 1,941 | +10.1% |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 137 | 9 | +1422.2% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | 137 | 9 | +1422.2% |
| Amortization Of Intangible Assets Not Associated With Single Function | 1,183 | 1,211 | -2.3% |
| Restructuring Charges And Acquisition Related Costs | 100 | 678 | -85.3% |
| Other Non-Operating Income (Expense) | 861 | 953 | -9.7% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | -116 | -78 | -48.7% |
| Income Before Taxes | 3,170 | 2,785 | +13.8% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | 6,838 | 7,069 | -3.3% |
| Biopharma [Member] · Operating Segments | 6,838 | 7,069 | -3.3% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -1,668 | -1,384 | -20.5% |
| Material Reconciling Items · Acquisition-Related Items [Member] | -504 | -282 | -78.7% |
| Material Reconciling Items · Amortization of Intangible Assets [Member] | -1,183 | -1,211 | +2.3% |
| Material Reconciling Items · Certain Significant Items [Member] | -312 | -1,407 | +77.8% |
| Income Tax Expense (Benefit) | 461 | -189 | +343.9% |
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | 2,709 | 2,973 | -8.9% |
| Income Loss From Discontinued Operations Net Of Tax | -13 | — | — |
| Net Income | 2,696 | 2,973 | -9.3% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | 8 | 6 | +33.3% |
| Parent | 2,687 | 2,967 | -9.4% |
| Retained Earnings | 2,687 | 2,967 | -9.4% |
| Net Income Loss Attributable To Noncontrolling Interest | 8 | 6 | +33.3% |
| Net Income | 2,687 | 2,967 | -9.4% |
| Income Loss From Continuing Operations Per Basic Share | 0.48 | 0.52 | -7.7% |
| EPS (Basic) | 0.47 | 0.52 | -9.6% |
| Income Loss From Continuing Operations Per Diluted Share | 0.47 | 0.52 | -9.6% |
| EPS (Diluted) | 0.47 | 0.52 | -9.6% |
| Wtd Avg Shares (Basic) | 5,691 | 5,675 | +0.3% |
| Wtd Avg Shares (Diluted) | 5,731 | 5,710 | +0.4% |
| Interest Income | -115 | -143 | +19.6% |
| Comprehensive Income | 3,554 | 2,229 | +59.4% |
| Net Income Loss Available To Common Stockholders Basic | 2,687 | 2,967 | -9.4% |
| Interest Expense | 668 | 654 | +2.1% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,703 | 1,430 | +19.1% |
| Accounts Receivable | 12,585 | 11,845 | +6.2% |
| Inventory | 10,667 | 10,852 | -1.7% |
| Other Tax Assets Current | 3,588 | 2,900 | +23.7% |
| Other Assets Current | 2,908 | 2,947 | -1.3% |
| Total Current Assets | 42,822 | 45,861 | -6.6% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 19,402 | 18,347 | +5.8% |
| Goodwill | 71,409 | — | — |
| Deferred Tax Assets Net And Other Tax Assets Noncurrent | 9,965 | 9,542 | +4.4% |
| Other Non-Current Assets | 9,834 | — | — |
| Total Assets | 207,618 | — | — |
| Intangible Assets | 30,918 | 34,622 | -10.7% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Developed Technology Rights | 29,905 | 33,180 | -9.9% |
| License Agreements and Other [Member] | 1,013 | 1,169 | -13.3% |
| Other Assets | |||
| Other Short Term Investments | 11,372 | 15,887 | -28.4% |
| Other Long Term Investments | 1,626 | 1,789 | -9.1% |
| Intangible Assets Net Excluding Goodwill | 52,559 | 53,976 | -2.6% |
| Current Liabilities | |||
| Debt Current | 3,890 | 4,470 | -13.0% |
| Accounts Payable | 4,506 | 5,240 | -14.0% |
| Taxes Payable Current | 3,130 | 3,105 | +0.8% |
| Employee Related Liabilities Current | 2,715 | 2,607 | +4.1% |
| Other Liabilities Current | 20,108 | — | — |
| Total Current Liabilities | 34,348 | 36,452 | -5.8% |
| Deferred Revenue (Current) (Q) | — | — | — |
Show Product Lines breakouts |
|||
| Paxlovid and Comirnaty [Member] · Government and Government Sponsored [Member] | 646 | — | — |
| Current Portion of Long-Term Debt | 3,861 | 3,749 | +3.0% |
| Non-Current Liabilities | |||
| Long-Term Debt | 60,565 | 57,639 | +5.1% |
Show Long-Term Debt Type breakouts |
|||
| Unsecured Debt | 60,565 | 57,639 | +5.1% |
| Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent | 1,984 | 2,021 | -1.8% |
| Deferred Tax Liabilities | 2,412 | 2,258 | +6.8% |
| Liability For Uncertain Tax Positions Noncurrent | 3,705 | 5,724 | -35.3% |
| Other Non-Current Liabilities | 14,200 | 13,297 | +6.8% |
| Total Liabilities | 117,214 | 117,391 | -0.2% |
| Long-Term Debt (Q) | — | — | — |
Show Derivative Risk breakouts |
|||
| Foreign currency long-term debt [Member] | 863 | 808 | +6.8% |
| Contract With Customer Liability Noncurrent (Q) | — | — | — |
Show Product Lines breakouts |
|||
| Paxlovid and Comirnaty [Member] · Government and Government Sponsored [Member] | 816 | 977 | -16.5% |
| Other Liabilities | |||
| Minority Interest | 303 | 299 | +1.3% |
| Stockholders' Equity | |||
| Common Stock | 482 | 481 | +0.2% |
| Additional Paid-In Capital | 94,773 | 93,856 | +1.0% |
| Treasury Stock Common Value | -115,190 | -115,008 | -0.2% |
| Retained Earnings | 117,238 | 119,590 | -2.0% |
| Accumulated Other Comprehensive Income | -7,203 | -8,581 | +16.1% |
| Total Stockholders' Equity | 90,101 | 90,338 | -0.3% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 90,404 | 90,637 | -0.3% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment Net Prior Service Cost Credit | 66 | 143 | -53.8% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -348 | -290 | -20.0% |
| Accumulated Net Unrealized Investment Gain Loss | 24 | 3 | +700.0% |
| Accumulated Other Comprehensive Income | -7,203 | -8,581 | +16.1% |
| Accumulated Translation Adjustment | -6,944 | -8,436 | +17.7% |
| Additional Paid In Capital | 94,773 | 93,856 | +1.0% |
| Common Stock | 482 | 481 | +0.2% |
| Noncontrolling Interest | 303 | 299 | +1.3% |
| Parent | 90,101 | 90,338 | -0.3% |
| Retained Earnings | 117,238 | 119,590 | -2.0% |
| Treasury Stock Common | -115,190 | -115,008 | -0.2% |
| Total Liabilities & Equity | 207,618 | 208,028 | -0.2% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 1,613 | 1,618 | -0.3% |
Show Business Segments breakouts |
|||
| Biopharma [Member] · Operating Segments | 348 | 331 | +5.1% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 78 | 74 | +5.4% |
| Material Reconciling Items · Amortization of Intangible Assets [Member] | 1,183 | 1,211 | -2.3% |
| Material Reconciling Items · Certain Significant Items [Member] | 3 | 4 | -25.0% |
| Asset Write Offs And Asset Impairment Charges | 32 | 344 | -90.7% |
| Deferred Income Taxes | -12 | -663 | +98.2% |
| Stock-Based Compensation | 272 | 170 | +60.0% |
| Pension And Other Postretirement Benefit Contributions Net Of Pension And Other Postretirement Benefit Expense | -173 | -229 | +24.5% |
| Other Non-Cash Items | -93 | 40 | -332.5% |
| Increase Decrease In Operating Capital | -1,732 | -1,919 | +9.7% |
| Net Cash from Operations | 2,615 | 2,335 | +12.0% |
| Investing Activities | |||
| Capital Expenditures | -436 | -564 | +22.7% |
| Payments To Acquire Short Term Investments | -2,569 | -2,823 | +9.0% |
| Proceeds From Sale Maturity And Collection Of Shortterm Investments | 4,576 | 3,955 | +15.7% |
| Payments For Proceeds From Short Term Investments With Original Maturities Of Three Months Or Less | -792 | -3,852 | +79.4% |
| Payments To Acquire Marketable Securities | -104 | -134 | +22.4% |
| Proceeds From Sale Maturity And Collection Of Longterm Investments | 88 | 82 | +7.3% |
| Other Investing Activities | 22 | 300 | -92.7% |
| Net Cash from Investing | 785 | 3,274 | -76.0% |
| Financing Activities | |||
| Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less | -127 | -386 | +67.1% |
| Payments Of Ordinary Dividends | -2,445 | -2,437 | -0.3% |
| Proceeds From Payments For Other Financing Activities | -284 | -356 | +20.2% |
| Net Cash from Financing | -2,856 | -5,227 | +45.4% |
| Supplemental | |||
| Income Taxes Paid | 72 | 152 | -52.6% |
| Interest Paid | 293 | 353 | -17.0% |
| Interest Paid Received Interest Rate Hedges | 62 | 74 | -16.2% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 19 | -7 | +371.4% |
| Net Change in Cash | 563 | 375 | +50.1% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,760 | 1,481 | +18.8% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.